ion of microRNA therapeutics. As
an innovator in RNA-based drug discovery and development, Isis is the owner
or exclusive licensee of over 1,500 issued patents worldwide. Additional
information about Isis is available at
http://www.isispharm.com.
ABOUT IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a majority-owned subsidiary of Isis
Pharmaceuticals, has developed and is commercializing the Ibis T5000(TM)
Biosensor System for rapid identification and characterization of
infectious agents. The Ibis T5000 is currently intended for research use
only and not for use in diagnostic procedures. It is capable of identifying
virtually all bacteria, viruses and fungi, and can provide information
about drug resistance, virulence and strain type of these pathogens.
Commercial applications for the Ibis T5000 Biosensor System include
epidemiologic surveillance, monitoring of pandemic diseases, identification
of emerging or previously unknown pathogens, forensic characterization of
human samples, identification of sources of hospital-associated infections,
and, in the future, human infectious disease diagnostics. Ibis develops,
manufactures and markets Ibis T5000 instruments and assay kits. Additional
information about Ibis can be found by selecting the Ibis link from Isis'
homepage at http://www.isispharm.com.
'/>"/>SOURCE Isis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results2.
deCODE genetics to Webcast Presentations at Annual R&D Event3.
deCODE genetics to Webcast Presentation at Piper Jaffray Europe Conference4.
Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference5.
Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 20086.
Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings7.
Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference8.
Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference9.
Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference10.
Telik Announces Presentation and Webcast at Needham Biotechnology Conference11.
Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management